Background
Methods
Patients and data collection
Treatment
D0.035 cc | D0.1 cc | D10.0 cc | D5.0 cc | V12 Gy | V15 Gy | V21 Gy | |
---|---|---|---|---|---|---|---|
Duodenum | ≤ 22.2 Gy | – | ≤ 11.4 Gy | ≤ 16.5 Gy | – | – | – |
Stomach | ≤ 22.2 Gy | – | ≤ 16.5 Gy | – | – | – | – |
Small Bowel | ≤ 25.2 Gy | – | – | ≤ 17.7 Gy | – | – | – |
Liver | – | – | – | – | – | ≤ 50% | ≤ 30% |
Kidneys (separate) | – | – | – | – | ≤ 25% | – | – |
Kidneys (together) | – | – | – | – | – | ≤ 35% | – |
Spinal cord | ≤ 21.0 Gy | ≤ 18.0 Gy | – | – | – | – | – |
Follow-up
BED calculation and radiobiological modelling
Statistical analysis
Results
Patient, tumour and treatment purpose characteristics (Table 2)
Gender | Male | N = 16 (38.0%) |
Female | N = 26 (62.0%) | |
Tumour stage | T4 | N = 37 (88.1%) |
T3 | N = 1 (2.4%) | |
T2 | N = 3 (7.1%) | |
T1 | N = 1 (2.4%) | |
Site | Head | N = 36 (86.0%) |
Body | N = 5 (12.0%) | |
Tail | N = 1 (2.0%) | |
PS (WHO) | 0 | N = 2 (5.0%) |
1 | N = 17 (41.0%) | |
2 | N = 22 (52.0%) | |
3 | N = 1 (2.0%) | |
Previous treatment | None | N = 8 (19.0%) |
Chemotherapy only | N = 23 (54.8%) | |
Chemoradiotherapy | N = 4 (9.5%) | |
Palliative surgery (gastric/biliary bypass) + chemotherapy | N = 2 (4.8%) | |
Curative surgery (Whipples/Resection) + chemotherapy | N = 1 (2.4%) | |
Curative surgery (Whipples/Resection) + chemoradiotherapy | N = 4 (9.5%) | |
SABR purpose | PRIMARY (no other/prior treatment) | N = 8 (19.0%) |
ADJUVANT (within 6 months other primary treatment) | N = 14 (33.3%) | |
CONSOLIDATION (> 6 months post-primary treatment to residual disease) | N = 11 (26.2%) | |
RETREAT (> 6 months post-primary treatment to disease relapse) | N = 9 (21.4%) |
SABR planning and delivery variables (Table 3)
Number of fiducials | 0 | N = 2 (5.0%)* |
1 | N = 8 (19.0%) | |
2 | N = 5 (12.0%) | |
3 | N = 21 (50.0%) | |
4 | N = 6 (14.0%) | |
Treatment duration (days) | 3 | N = 37 (88.1%) |
4 | N = 1 (2.4%) | |
5 | N = 3 (7.1%) | |
7 | N = 1 (2.4%) | |
PET scan data used for planning | Yes | N = 11 (26.0%) |
No | N = 31 (74.0%) | |
PTV size (cc) | Mean (95% CI) | 76.25 (63.83–88.67) |
Prescription dose (Gy) | Mean (95% CI) | 26.77 (19.33–113.39) |
Prescription Isodose (%) | Mean (95% CI) | 67.3 (65.24–69.35). |
Percentage Cover (%) | Mean (95% CI) | 96.6 (95.52–97.66) |
Min dose to PTV (Gy) | Mean (95% CI) | 22.29 (21.0–23.5) |
Max dose to PTV (Gy) | Mean (95% CI) | 40.2 (38.5–41.9) |
Mean dose to PTV (Gy) | Mean (95% CI) | 31.5 (30.8–32.3) |
Homogeneity Index (HI) | Mean (95% CI) | 1.5 (1.45–1.55) |
BED (Gy) | Mean (95% CI) | 50.3 (47.7–53.0) |
Fraction dose (Gy per fraction) | Mean (95% CI) | 8.9 (8.6–9.2) |
Delivery time (mins) | Mean (95% CI) | 71.4 (65.2–77.6) |
Acute and late treatment toxicity incidence (Table 4)
Grade 1–2 | Grade 3 | Grade 4 | |
---|---|---|---|
Acute (≤ 3 months post-treatment) toxicity incidence in N = 37 patients | |||
NONE | N = 11 (30%) | ||
Diarrhoea | N = 5 (14%) | 0 | 0 |
Nausea | N = 8 (22%) | 0 | 0 |
Vomiting | N = 2 (5%) | 0 | 0 |
Dyspepsia | N = 2 (5%) | 0 | 0 |
Anorexia | N = 2 (5%) | 0 | 0 |
Pain | N = 7 (19%) | N = 1 (3%) | 0 |
Fatigue | N = 11 (30%) | N = 1 (3%) | 0 |
Jaundice | N = 1 (3%) | 0 | 0 |
Obstructive Jaundice | 0 | N = 1 (3%) | 0 |
Late (> 3 months post-treatment) toxicity incidence in N = 32 | |||
NONE | N = 27 (84%) | ||
Pain | N = 1 (3%)* | 0 | 0 |
Nausea | N = 1 (3%)* | 0 | 0 |
Pancreatic Insufficiency | N = 1 (3%) | 0 | 0 |
GI Bleeding | 0 | 0 | N = 2 (6%) |
Duodenal Stricture | 0 | 0 | N = 2 (6%) |
Association of SABR planning and delivery variables with toxicity incidence (Tables 5 and 6)
Acute toxicity max grade (n = 37) | Late toxicity max grade (n = 32) | |||||||
---|---|---|---|---|---|---|---|---|
0 | 1–2 | 3 | p-value | 0 | 2 | 4 | p-value | |
Number of fiducials† | ||||||||
0–1 | 1 | 6 | 0 | 0.0002* | 4 | 1 | 2 | 0.01* |
2–4 | 10 | 17 | 3 | 22 | 1 | 2 | ||
Treatment days † | ||||||||
3 | 11 | 20 | 3 | 0.37 | 25 | 2 | 2 | 0.012* |
4–7 | 0 | 3 | 0 | 1 | 0 | 2 | ||
Previous surgery† | ||||||||
Yes | 1 | 5 | 0 | 0.47 | 4 | 0 | 1 | 0.68 |
No | 10 | 18 | 3 | 22 | 2 | 3 | ||
Previous irradiation† | ||||||||
Yes | 0 | 7 | 1 | 0.11 | 6 | 0 | 0 | 0.43 |
No | 11 | 16 | 2 | 20 | 2 | 4 | ||
Min dose to PTV† | ||||||||
< 22.35Gy | 5 | 10 | 2 | 0.75 | 9 | 2 | 2 | 0.17 |
≥ 22.35Gy | 6 | 11 | 1 | 17 | 0 | 2 | ||
SABR purpose† | ||||||||
Sole primary | 1 | 6 | 0 | 0.064 | 6 | 1 | 0 | 0.62 |
Adjuvant | 6 | 4 | 1 | 7 | 0 | 1 | ||
Consolidation | 4 | 6 | 1 | 8 | 1 | 1 | ||
Retreat | 0 | 5 | 2 | 5 | 0 | 2 | ||
Treatment time (mins) | 77.5 | 69.9 | 68.3 | 0.570 | 67.7 | 59.5 | 83.0 | 0.045* |
PTV (cc) ‡ | 93.5 | 72.1 | 67.9 | 0.355 | 77.2 | 61.5 | 79.3 | 0.875 |
PTV min dose (cGy) ‡ | 2342.6 | 2227.6 | 2115.8 | 0.605 | 2317.7 | 1901.5 | 2332.4 | 0.396 |
PTV max dose (cGy) ‡ | 3951.3 | 3974.7 | 4149.2 | 0.8819 | 4120.6 | 3920.5 | 3861.9 | 0.622 |
PTV mean dose (cGy) ‡ | 3151.9 | 3118.0 | 3241.9 | 0.879 | 3225.4 | 3085.6 | 3015.0 | 0.493 |
Prescription dose (cGy) ‡ | 2736.4 | 2647.8 | 2700.0 | 0.735 | 2740.4 | 2700.0 | 2612.5 | 0.7067 |
Prescription isodose (%) ‡ | 69.6 | 67.5 | 65.3 | 0.554 | 67.0 | 69.0 | 68.3 | 0.882 |
Percentage cover (%) ‡ | 96.1 | 97.0 | 97.3 | 0.771 | 97.1 | 88.1 | 91.1 | 0.002* |
BED (Gy10) ‡ | 52.3 | 49.2 | 52.0 | 0.650 | 52.1 | 51.0 | 49.0 | 0.811 |
HI ‡ | 1.44 | 1.50 | 1.54 | 0.523 | 1.51 | 1.46 | 1.47 | 0.833 |
Grade 3+ Toxicity | Treatment Factors | Duodenal Dosimetry | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Fids | PTV | Prescribed Dose | Dur’n | D0.035 cc | D1.0 cc | D5.0 cc | D10.0 cc | V15 Gy | V20 Gy | |
ACUTE | ||||||||||
Grade 3 pain | 4 | 39.84 cc | 30.0 Gy 3 fractions | 3 days | 33.9 Gy* | 25.4 Gy | 15.8 Gy | 12.8 Gy* | 5.9 cc | 2.5 cc |
Grade 3 fatigue | 3 | 44.22 cc | 30.0 Gy 3 fractions | 3 days | 34.9 Gy* | 27.9 Gy | 20.5 Gy* | 16.2 Gy* | 12.3 cc | 5.4 cc |
Grade 3 obstructive jaundice | 4 | 119.57 cc | 21.0 Gy 3 fractions | 3 days | 23.8 Gy* | 22.6 Gy | 21.1 Gy* | 19.6 Gy* | 32.2 cc | 8.6 cc |
LATE | ||||||||||
Grade 4 duodenal stricture | 1† | 20.34 cc | 28.5 Gy 3 fractions | 5 days | 11.2 Gy | 8.3 Gy | 6.8 Gy | 6.2 Gy | 0.0 cc | 0.0 cc |
Grade 4 GI bleed | 1† | 83.49 cc | 27.0 Gy 3 fractions | 5 days | 29.3 Gy* | 28.3 Gy | 26.2 Gy* | 23.9 Gy* | 39.1 cc | 19.4 cc |
Grade 4 GI bleed | 3 | 109.31 cc | 22.0 Gy 3 fractions | 3 days | 24.2 Gy* | 23.2 Gy | 22.5 Gy* | 21.8 Gy* | 63.3 cc | 24.3 cc |
Grade 4 duodenal stricture | 3 | 104.25 cc | 27.0 Gy 3 fractions | 3 days | 31.6 Gy* | 29.1 Gy | 26.0 Gy* | 21.8 Gy* | 24.2 cc | 12.8 cc |
Survival outcomes (Fig. 1) and association with planning and delivery variables
LQ radiobiological modelling: Comparison of calculated parameters (Table 7)
Total Dose (D) | Fraction Dose (d) | Fractions (n) | Duration (days) | BED (Gy10) | BED (Gy3) | |
---|---|---|---|---|---|---|
Comparator regimen (100% dose to PTV) | 50.4 Gy | 1.8 Gy | 28 | 37 | 40.5 Gy | 80.6 Gy |
SABR equivalent | 23.55 Gy | 7.85 Gy | 3 | 3 | 40.5 Gy | 77.0 Gy |
Number of patients treated with total dose ≥ 23.55 Gy = 39/42 (92.9%) | ||||||
Comparator regimen (min 95% dose to PTV) | 47.88 Gy | 1.71 Gy | 28 | 37 | 37.5 Gy | 75.27 Gy |
SABR equivalent | 22.35 Gy | 7.45 Gy | 3 | 3 | 37.5 Gy | 77.85 Gy |
Number of patients treated with minimum PTV dose ≥ 22.35 Gy = 21/42 (50%) |